News

FDA Approves COMETRIQ™ (Cabozantinib) To Treat Medullary Thyroid Cancer

CAPRELSA(vandetanib) News — 2011
AstraZeneca has developed the “CAPRELSA Patient Access Services,” or CPAS to assess patients’ insurance coverage and direct patients to appropriate sources for financial assistance for which they may be eligible. The CPAS phone number is 800-367-4999. The CAPRELSA REMS program is at http://www.caprelsarems.com

FDA Approves Vandetanib on April 6, 2011

Letters to the FDA Support Vandetanib

ThyCa Participates at FDA Hearing on Vandetanib

Douglas Ball, M.D., To Speak on May 10, 2008, at Mid-Atlantic Thyroid Cancer Survivors’ Workshop near Washington, DC.

Medullary thyroid cancer specialist Douglas Ball, M.D., Endocrinologist at Johns Hopkins Hospital in Baltimore, Maryland, will speak and answer questions about medullary thyroid cancer at the 7th Annual Mid-Atlantic Thyroid Cancer Survivors’ Workshop.

The workshop will take place in Falls Church, Virginia (near Washington, DC) on Saturday, May 10, 2008. The event starts at 8 a.m. and goes until 5 p.m.

A thyroid surgeon and several other physicians will also speak at this free one-day event. This workshop is open to anyone interested in thyroid cancer.

Janis I. Halzel, Pharm.D., Co-Moderator of the ThyCa Medullary Thyroid Cancer E-Mail Group, will lead roundtable discussions for medullary thyroid cancer survivors and caregivers.

Special room rates have been arranged at a hotel located near the workshop.

For details about the speakers, schedule, hotel, and transportation directions, visit ThyCa's Conferences page.

The free workshop is one of several special events sponsored this spring by the national nonprofit organization ThyCa: Thyroid Cancer Survivors’ Association, Inc.. Throughout the year, ThyCa also sponsors free local support groups, person-to-person support, e-mail groups, a survivors' toll-free number, and many other services and resources. Details are available on the ThyCa web site or by calling toll-free 1-877-588-7904.